The six-minute walk test (6MWT) has been widely used as an objective evaluation of functional exercise capacity and response to medical intervention in cardiopulmonary diseases. However, little is known about the 6MWT in evaluating patients with AL amyloidosis. We performed a retrospective study of 120 adults with systemic AL amyloidosis (60 with cardiac involvement and 60 without cardiac involvement) who had their initial evaluation at the Amyloidosis Center between 2013 and 2015 and had undergone 6MWT as a measure of functional exercise capacity. Forty-seven patients with cardiac involvement and 41 patients without cardiac involvement were included in the final analysis. The six-minute walk distances (6MWD) were 368 AE 105 m and 420 AE 116 m (mean AE SD), respectively (P = 0Á03). Among AL amyloidosis patients with cardiac involvement, the 6MWD was associated with New York Heart Association class (P < 0Á001), B-type natriuretic peptide (P = 0Á003) and overall survival (hazard ratio 0Á381, 95% confidence interval 0Á215-0Á676, P = 0Á001). In conclusion, the 6MWT is a valuable tool in assessing functional exercise capacity in patients with AL amyloidosis.
Light chain (AL) amyloidosis is a systemic disorder caused by extracellular deposition of amyloid fibrils derived from monoclonal immunoglobulin light chain fragments from a plasma cell dyscrasia. It is the most common type of systemic amyloidosis in developed countries. Cardiac involvement occurs in over 50% of patients with AL amyloidosis, and is the leading cause of morbidity and mortality (Falk, 2005) . Without treatment, median survival is only 6 months in AL amyloidosis patients with symptomatic heart failure (Grogan & Dispenzieri, 2015) . Functional measures that are easily performed and are reproducible are needed for longitudinal assessment of patients with AL amyloidosis. Therapies for cardiac AL amyloidosis are currently limited, but several trials for new drugs are underway, including monoclonal antibodies against soluble and insoluble amyloid aggregates (Mahmood et al, 2014; Richards et al, 2015; Gertz et al, 2016; Wechalekar et al, 2016) . Phase II and phase III randomized clinical trials are currently ongoing for the monoclonal antibodies against amyloid fibrils, specifically NEOD001. One of the secondary endpoints used in these trials is cardiac functional response, using the 6-minute walk test (6MWT) as a surrogate endpoint (NCT02312206) however, not much is known about the 6MWT in this specific patient population. Furthermore, the 6MWT is also being used as a secondary endpoint in the phase III randomized clinical trials of tafamidis (NCT01994889) and revusiran (NCT02319005) in transthyretin amyloid (ATTR) cardiomyopathy.
The 6MWT is a widely used objective measure of functional exercise capacity in patients with cardiopulmonary diseases. It measures the distance patients can walk in 6 min along 30-m long hallways. While most patients do not achieve maximal aerobic exercise capacity during the 6MWT, activities of daily living are usually performed at a walking pace, so the 6MWT may be a better representation of functional exercise capacity. Importantly, the 6MWT has been used as a surrogate endpoint in many systolic heart failure drug trials since 1988 (Olsson et al, 2005) . It has been used in randomized clinical trials of angiotensin-convertingenzyme (ACE) inhibitors (De Bock et al, 1994; Lang et al, 1997) , beta blockers (Packer et al, 1996; Genth-Zotz et al, 2000) , and cardiac resynchronization in heart failure patients research paper First published online 24 March 2017 doi: 10.1111/bjh.14586 (Abraham et al, 2002) . The use of the 6MWT as a predictor of morbidity and mortality in heart failure is more controversial: the 6MWT is more accurate when it reflects maximal exercise capacity, as is seen in more severe cases of heart failure (Bittner et al, 1993) . For instance, one study of New York Heart Association (NYHA) class II and III heart failure patients associated a 6-min walk distance (6MWD) of less than 300 m with worse prognosis (Roul et al, 1998) . Most trials incorporating the 6MWT have focused on heart failure with reduced ejection fraction, as have the majority of the medical interventions, but, as heart failure with preserved ejection fraction (HFpEF) becomes more prevalent, more medical interventions are targeting this patient population and using the 6MWT as a surrogate endpoint (Redfield et al, 2015) . HFpEF is the most common presentation for patients with AL amyloidosis.
The purpose of this study was to examine the 6MWT as a functional measure in patients with systemic AL amyloidosis with and without cardiac involvement. We also compared mean 6MWD in patients with systemic AL amyloidosis with and without cardiac involvement.
Methods
This study was approved by the Institutional Review Board of Boston Medical Center, and all patients signed informed consent as per the Declaration of Helsinki. Inclusion criteria included age greater than 18 years, systemic AL amyloidosis and completion of the 6MWT. We reviewed the charts of consecutive AL amyloidosis patients with and without cardiac involvement evaluated at the Amyloidosis Center of Boston University School of Medicine. All new patients to the Amyloidosis Center are referred for the 6MWT, which is performed alongside pulmonary function testing and stair climb testing. Patients were allowed to pause and rest during the 6 minutes of the test, because the test is self-paced.
Cardiac involvement was determined by a cardiologist with expertise in amyloid heart disease, as a member of the multidisciplinary Amyloidosis Clinical Team, by using a combination of consensus criteria and diagnostic tools, including echocardiography, electrocardiography (ECG), cardiac biomarkers including B-type natriuretic peptide (BNP) and troponin I, cardiac magnetic resonance imaging and endomyocardial biopsy (Gertz et al, 2005; Palladini et al, 2012) .
The 6MWT results, pulmonary function testing, demographic information, previous and recommended treatment plans and New York Heart Association (NYHA) classes were abstracted from the electronic medical record of patients who met the inclusion and exclusion criteria. The patients were followed until death or 31 January 2016, when the charts were all abstracted. The other data, such as cardiac biomarkers and echocardiogram results, were extracted from the Amyloidosis Center database. Statistical analyses were performed with Statistical Analysis System version 9Á3 (SAS Institute Inc., Cary, NC, USA) and 14Á0Á372 (StataCorp LP, College Station, TX, USA). The two-tailed Student's t-test, chi-square test and analysis of variance were used, as appropriate, to compare the data between the two groups. Pvalues ≤ 0Á05 were considered to be statistically significant. Hazard ratios were calculated using the Cox proportional hazard ratio. Correlation was calculated using the Pearson correlation coefficient.
Results
Sixty consecutive AL amyloidosis patients with cardiac involvement and 60 without cardiac involvement who had initial evaluations at the Boston University Amyloidosis Center between July 2013 and June 2015 were included. Among the patients with cardiac involvement, ten did not attempt the 6MWT and additionally three were excluded because they complained of severe pain during the test. Of the ten who did not attempt the 6MWT, five who were NYHA class IV and three who were NYHA class III declined testing due to their debilitating illness. Another patient was lost to follow-up and another was not allowed to complete the 6MWT due to hypoxia. Ultimately, 47 patients with cardiac involvement were included in the initial analyses (Fig 1) .
Among the patients without cardiac involvement, four did not attempt the 6MWT, three were excluded due to pain experienced during the 6MWT, five were excluded due to equivocal cardiac involvement, and seven were excluded because they only had localized AL amyloidosis after chart review. Of those four AL amyloidosis patients without cardiac involvement who did not attempt the 6MWT, two were lost to follow-up and two did not attempt it due to debilitation from their disease. Finally, 41 AL amyloidosis patients without cardiac involvement were included in the initial analysis (Fig 1) .
Patient characteristics are shown in Table I . All the characteristics were well balanced in both groups of AL amyloidosis patients with and without cardiac involvement (Table II) . The median difference between involved and uninvolved free light chains (dFLC) was not statistically different between the two groups (106Á5 vs. 31Á6 mg/l, P = 0Á17). Among the criteria for cardiac involvement, including BNP and troponin I levels, left ventricle ejection fraction (LV EF) and interventricular septal end diastole thickness (IVSd), there was an expected statistically significant difference between the patients with cardiac involvement and without cardiac involvement. There was no significant difference in the amount of proteinuria between the two groups. The mean 6MWD for AL amyloidosis patients with cardiac involvement was 368 AE 105 (AESD) m versus 420 AE 116 m in AL amyloidosis patients without cardiac involvement (P = 0Á03) (Fig 2) .
Among the AL amyloidosis patients with cardiac involvement, 34% (16/47) of patients were NYHA class I at the time of the 6MWT, 45% (21/47) were NYHA class II, and 21% (10/47) were NYHA class III. None were NYHA class IV, as the five patients who were NYHA class IV did not attempt the 6MWT due to debilitation from their disease. The mean 6MWD among these different NYHA classes were 426, 370 and 273 m, respectively (P < 0Á001) (Fig 3) . There was a statistically significant correlation between NYHA class and the 6MWT (P < 0Á001). Their mean age, height and body mass index (BMI) were not significantly different, and these variables did not correlate with the 6MWT (Table III) . Adjusting for age, sex, height and weight did not change the results. There was an expected difference in mean BNP, LV EF, and IVSd between the three NYHA class groups.
There was a significant correlation between 6MWT and BNP (P = 0Á003). For AL amyloidosis patients with BNP <200 pg/ml, mean 6MWD was 417 AE 15 m; for BNP 200-500 pg/ml, mean 6MWD was 399 AE 23 m; and for patients with BNP > 500 pg/ml, mean 6MWD was 315 AE 25 m.
Using the Cox proportional hazards model on all patients, the 6MWT also showed a significant association with survival for all patients [hazard ratio (HR), 0Á38, 95% confidence interval (CI), 0Á215-0Á676, P = 0Á001] for each standard deviation (SD) change, 113 m for all patients. The other variables that also had a significant association with survival included BNP (HR 1Á84, 95% CI 1Á35-2Á5, P = 0Á0001, SD 657), LV EF (HR 0Á53, 95% CI 0Á357-0Á784, P = 0Á0015, SD 11Á4), troponin I (HR 1Á41, 95% CI 1Á04-1Á91, P = 0Á2, SD 0Á028), IVSd (HR 1Á79, 95% CI 1Á12-2Á86, P = 0Á014, SD 3), forced expiratory volume 1 in 1 s (HR 0Á522, 95% CI 0Á30-0Á92, P = 0Á024, SD 22Á3) and forced vital capacity) (HR 0Á557, 95% CI 0Á32-0Á96, P = 0Á034, SD 22Á1), which all reflect cardiac involvement.
The mean time from diagnosis to evaluation at our Amyloidosis Center was 5Á3 months for those with cardiac involvement and 9Á3 months for those without. In addition, 25 (53%) of the cardiac AL amyloidosis patients and 17 (41%) of the AL amyloidosis patients without cardiac involvement had prior therapy before presenting to our centre for initial evaluation, but this was not statistically significant. Moreover, the types of interventions the patients received prior to the 6MWT were similar between the two groups. After their evaluations, the majority of the patients were recommended further therapy (Table IV) .
In a post-hoc analysis, we included patients who did not attempt the 6MWT due to debilitating illness by defining their 6MWD as zero m. Here, 55 AL amyloidosis patients with cardiac involvement and 43 without cardiac involvement were included. There was no significant difference in any of the results. In this post-hoc analysis, the mean 6MWD was 315 AE 163 m for those with cardiac involvement versus 400 AE 144 m for those without cardiac involvement (P < 0Á01). Among these patients, 15 of 55 (27%) cardiac involvement died during a median follow-up of 17Á5 months (range 1Á3-31Á5).
Discussion
The 6MWT is an objective measure of functional exercise capacity used in many diseases that affect exercise tolerance, but especially in heart failure. It is a simple test of how far patients can walk at a normal pace in 6 min. Because of its self-paced style, it is better reflective of normal activities of daily living. Age, gender and BMI are the most important variables that affect the 6MWT, and several reference equations for healthy individuals have been proposed using these variables. As expected, the 6MWD decreases with age and BMI, and men walk 30 m farther than women on average. 6MWD, 6-min walk distance; ANS, autonomic nervous system; BNP, B-type natriuretic peptide; dFLC, difference between involved and uninvolved free light chains; GI, gastrointestinal system; IVSd, interventricular septal end diastole thickness; LV EF, left ventricle ejection fraction; NYHA, New York Heart Association; PNS, peripheral nervous system; SD, standard deviation. For a reference, the mean 6MWD of a healthy cohort with a similar age as our cohort was 571 AE 90 m (Casanova et al, 2011) . There is extensive data for the use of the 6MWT as a measure of response to medical intervention in many systolic heart failure trials, including randomized controlled trials of cardiac resynchronization, ACE inhibitors and beta-blockers. Now it is also being used as a surrogate endpoint in clinical trials for HFpEF (Redfield et al, 2015) . The 6MWT has also been validated as a single measure of functional capacity in these patient populations (Pollentier et al, 2010; Palau et al, 2016) . In addition, the 6MWT has been used as a primary endpoint for the approval of treatments for several rare multi-organ diseases. However, to our knowledge, there is no published data for the use of the 6MWT in systemic AL amyloidosis with cardiac involvement, which is a rare but important cause of heart failure. Data presented at the 2016 American Society of Hematology Annual Meeting and unpublished data presented at the XVth International Symposium on Amyloidosis in July 2016 showed that the 6MWT can be used as a measure of response to therapy in AL amyloidosis patients (Decker et al, 2015; unpublished observations) . Meanwhile, the 6MWT is currently being used as a secondary endpoint in randomized clinical trials of novel therapeutics for this disease, such as NEOD001, an immunoglobulin G1 antibody against amyloid fibrils.
In this retrospective case series, the mean 6MWD of AL amyloidosis patients with cardiac involvement was 368 m, which was significantly shorter than the 420 m walked by the AL amyloidosis patients without cardiac involvement. As expected, cardiac involvement confers significantly more morbidity and mortality in AL amyloidosis patients (Grogan & Dispenzieri, 2015) . This average difference of 52 m between our two cohorts, while small, is probably clinically significant. For instance, the minimal clinically important change in the 6MWT was only 25 m in a cardiac rehabilitation study (Gremeaux et al, 2011) and between 54 and 80 m in a COPD study (Redelmeier et al, 1997) . Moreover, we found that for every additional 113 m (or 1 SD) walked, there was a 62% decrease in mortality.
The baseline characteristics of the two groups were similar, so other variables are unlikely to account for the difference. If we include the patients who were too debilitated to walk at all as having walked a distance of zero m, the results are even more disparate: 315 m for patients with cardiac involvement versus 400 m for patients without cardiac involvement 
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IMiD, immune modulator therapy; Mel, melphalan-based therapy; NonSCT, non stem cell transplantation; PI, proteasome inhibitor; SCT, stem cell transplantation; SD, standard deviation. Of note, all percentages are in relation to the total N.
(P < 0Á01). When these patients who were too debilitated to attempt the test were included in the analysis, there was no significant change in any of the results (not shown), and thus should not impact the applicability of the test. In fact, not being able to complete the test in itself reflects a poor functional capacity. Importantly, the distance walked by AL amyloidosis patients without cardiac involvement is also significantly less than a healthy individual would walk (over 100 m difference), mostly due to comorbidities of peripheral oedema and fatigue, as 85% of the patients without cardiac involvement had kidney involvement. Our results are similar to previous 6MWT studies in heart failure of all aetiologies. For instance, in a cohort of patients with NYHA class II and III systolic heart failure, the mean 6MWD was 396 m (Opasich et al, 2001) . In another study with NYHA class II and III HFpEF patients, the mean 6MWD was 321 m (Redfield et al, 2015) .
In our case series, the 6MWT was also associated with NYHA class (P < 0Á001), another well validated, albeit more subjective, measure of exercise capacity. This association was unchanged after adjusting for age, gender, weight and height, which are the other known variables affecting the 6MWT. The average 6MWD was only 273 m for patients with NYHA class III, and none of the five patients with NYHA class IV disease could attempt the 6MWT. Meanwhile, the average 6MWD of the patients classified as NYHA class I (426 m) was similar to that of the AL amyloidosis patients without cardiac involvement (420 m). NYHA class I patients should have no limitation to their physical activity, at least with regards to their cardiac function, and thus should behave more like AL amyloidosis patients without cardiac involvement. Baseline characteristics were similar among the three classes, making these variables unlikely to affect the differences seen in the 6MWT.
N-terminal pro b-type natriuretic peptide (NT-proBNP) has been validated as a functional biomarker predictive of survival in cardiac amyloidosis . Here, we showed a correlation between 6MWT and BNP. The 6MWT is a surrogate for functional exercise capacity, especially important in determining treatment regimens, which cannot be approximated by a biomarker alone. Thus, these two tests complement each other, reflecting both the patient's degree of amyloid burden and its effect on functional exercise capacity.
This study has several limitations. First, as a retrospective study, the 6MWD was only measured at baseline, but not after treatment. The 6MWT also could not be correlated to maximal oxygen consumption (or peak VO2), which would enhance its validation as a single measure of functional exercise capacity. In future studies, these two analyses should be targeted to enhance our knowledge of the 6MWT in systemic AL amyloidosis patients. Second, many patients were referred to our tertiary care centre after receiving prior treatment. However, this was well balanced between the two groups. Finally, the AL amyloidosis patients with cardiac involvement also had more peripheral nervous system involvement compared to the patients without cardiac involvement (26% vs. 7%). It is possible that this contributed to the difference in the 6MWD between the two groups, but would not explain the marked difference in 6MWD between the different NYHA classes.
In conclusion, the 6MWT is a simple, objective measure of functional exercise capacity that is associated with NYHA class and survival in AL amyloidosis patients. These results could be used as a framework in validation of endpoints for clinical trials of therapies in this rare disease, AL amyloidosis.
